Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia-Reference-Cited by-同舟云学术

Incremental cost-effectiveness analysis of tyrosine kinase inhibitors in advanced non-small cell lung cancer with mutations of the epidermal growth factor receptor in Colombia

Published:2020-07-07 Issue:4 Volume:21 Page:821-827
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Lasalvia Pieralessandro¹,Hernández Fabián¹,Gil-Rojas Yaneth¹,Rosselli Diego²^ORCID

Affiliation:

1. Health Economics Department, Neuroeconomix, Bogota, Colombia

2. Clinical Epidemiology and Biostatistics Department, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia

Funder

Boehringer Ingelheim Colombia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2020.1779063

Reference35 articles.

1. A Review of Treatment in Non-small-cell Lung Cancer

2. Cancer Statistics, 2009

3. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

4. The biology and management of non-small cell lung cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic evaluation ofWolbachiadeployment in Colombia: A modeling study;2024-07-05

2. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

3. Treatment for Advanced Non–Small Lung Cancer (NSCLC) with Mutated EGFR in Low- and Middle-Income Countries (LMICs);Journal of Immunotherapy and Precision Oncology;2023-11-01

4. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma;Blood;2022-12-22

5. A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC);Expert Opinion on Pharmacotherapy;2022-07-04